ArticleWorld journal of gastroenterology2025
Pancreatic steatosis is not associated with advanced steatohepatitis or fibrosis in metabolic dysfunction-associated steatotic liver disease.
Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVisceral fat deposition in the pancreas in the absence of significant alcohol use is termed non-alcoholic fatty pancreas disease (NAFPD) and is closely associated with metabolic dysfunction-associated steatotic liver disease (MASLD). However, few studies have assessed the relationship between the severity of NAFPD and the degree of hepatic inflammation and fibrosis in patients with MASLD.
aimTo evaluate how NAFPD correlates with degrees of hepatic steatosis, steatohepatitis, and hepatic fibrosis in patients with MASLD.
methodsWe performed a retrospective cohort study of patients in the Yale New Haven Health System with a diagnosis of MASLD. Chart and primary imaging data were reviewed to evaluate the degree of pancreatic steatosis and its relationship to hepatic steatosis, steatohepatitis, fibrosis, and other metabolic parameters.
resultsNinety-nine participants were identified who met additional inclusion criteria (liver biopsy and non-contrast enhanced computed tomography scan of the abdomen). 76 out of the 99 patients in our cohort met the imaging criteria for NAFPD. However, there was no association between the degree of pancreatic steatosis and hepatic steatosis (either on imaging or biopsy), or the degree of pancreatic steatosis and advanced forms of MASLD, such as the degree of metabolic dysfunction-associated steatohepatitis or stage of hepatic fibrosis.
conclusionMASLD and NAFPD are co-occurring diseases resulting from and contributing to metabolic dysregulation. Our study confirms this association but does not support a strong association between pancreatic steatosis and hepatic steatohepatitis or fibrosis in this cohort; larger prospective, longitudinal studies are needed in the future to better define the complex interplay of MASLD, NAFPD, and metabolic health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.